National News
Senate Advances Reauthorization of Critical ALS Therapy Access Legislation
Content Files PDF XML TEXT Metadata download Descriptive Metadata (MODS) Preservation Metadata (PREMIS) All Content and Metadata files, including granules ZIP
Last updated:
Key points
- The U.S. Senate passed S. 4472 to reauthorize critical research and therapy access for ALS patients.
- The legislation aims to streamline early access to experimental treatments for neurodegenerative diseases.
- Official legislative documentation was published following Senate engrossment of the bill.
NewsWK — The United States Senate has passed S. 4472, the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, extending federal support for research and patient access to treatments for neurodegenerative diseases, according to legislative records published by GovInfo.
The bill reauthorizes key federal grant programs designed to accelerate clinical trials and expand early access to promising therapies for patients suffering from Amyotrophic Lateral Sclerosis (ALS). The legislation focuses on streamlining the pipeline for innovative medical treatments while preserving statutory safety standards.
Healthcare advocates and lawmakers have emphasized the importance of maintaining predictable funding mechanisms for rare disease research to incentivize private-sector innovation and offer practical options to families facing terminal diagnoses.
Based on reporting originally published by GovInfo (U.S. GPO). Read the original story.
